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Abstract: Over the two last decades, venom toxins have been explored as alternatives to opioids
to treat chronic debilitating pain. At present, approximately 20 potential analgesic toxins, mainly
from spider venoms, are known to inhibit with high affinity the NaV1.7 subtype of voltage-gated
sodium (NaV) channels, the most promising genetically validated antinociceptive target identified so
far. The present study aimed to consolidate the development of phlotoxin 1 (PhlTx1), a 34-amino acid
and 3-disulfide bridge peptide of a Phlogiellus genus spider, as an antinociceptive agent by improving
its affinity and selectivity for the human (h) NaV1.7 subtype. The synthetic homologue of PhlTx1
was generated and equilibrated between two conformers on reverse-phase liquid chromatography
and exhibited potent analgesic effects in a mouse model of NaV1.7-mediated pain. The effects of
PhlTx1 and 8 successfully synthetized alanine-substituted variants were studied (by automated
whole-cell patch-clamp electrophysiology) on cell lines stably overexpressing hNaV subtypes, as
well as two cardiac targets, the hCaV1.2 and hKV11.1 subtypes of voltage-gated calcium (CaV) and
potassium (KV) channels, respectively. PhlTx1 and D7A-PhlTx1 were shown to inhibit hNaV1.1–1.3
and 1.5–1.7 subtypes at hundred nanomolar concentrations, while their affinities for hNaV1.4 and 1.8,
hCaV1.2 and hKV11.1 subtypes were over micromolar concentrations. Despite similar analgesic effects
in the mouse model of NaV1.7-mediated pain and selectivity profiles, the affinity of D7A-PhlTx1 for
the NaV1.7 subtype was at least five times higher than that of the wild-type peptide. Computational
modelling was performed to deduce the 3D-structure of PhlTx1 and to suggest the amino acids
involved in the efficiency of the molecule. In conclusion, the present structure–activity relationship
study of PhlTx1 results in a low improved affinity of the molecule for the NaV1.7 subtype, but without
any marked change in the molecule selectivity against the other studied ion channel subtypes. Further
experiments are therefore necessary before considering the development of PhlTx1 or synthetic
variants as antinociceptive drug candidates.
Keywords: Phlogiellus spider; phlotoxin 1; human voltage-gated ion channel subtypes; NaV1.7
channel subtype; mouse model of NaV1.7-mediated pain
Key Contribution: This publication describes an optimized procedure of folding of a spider ICK
toxin presenting two conformations under reverse phase liquid chromatography analysis. Thanks
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to its first structure–activity relationship study, a variant with improved affinity was generated and
validated in vivo as a pain killer.
1. Introduction
More than 10% of the worldwide population is complaining about pain [1]. The first order neurons
involved in pain transmission from the periphery to the central nervous system are the dorsal root
ganglion (DRG neurons). These neurons express a multitude of transmembrane proteins, such as
G-protein-coupled receptors (GPCRs) and ion channels, which can be considered as targets for the
therapeutic treatment of pain. Hence, some molecules interacting with GPCRs or ion channels have
been reported to be involved in pain relief [2–6]. However, in developed countries, and mainly in the
United States, an overconsumption of opioids is observed due to unjustified medical prescriptions,
as well as acquisition of tolerance and dependence of patients to these GPCR-targeting painkillers.
Finding pharmacological, chirurgical, and behavioral alternatives has thus become a priority [7,8].
In this context, venom toxins have been explored over the two last decades as an original source
of innovative antinociceptive drugs targeting different ion channel subtypes. One of these toxins,
the ω-conotoxin-MVIIA isolated from a cone snail which inhibits the N-type, CaV2.2 subtype of
voltage-gated calcium (CaV) channels, was commercialized as Prialt®after FDA approval in 2004.
However, the narrow spectrum of use of this molecule, its intrathecal route of administration, and
associated side-effects, represent major drawbacks for the treatment of chronic debilitating pain [9].
Among voltage-gated sodium (NaV) channels, the NaV1.7 subtype was widely reported to be the most
incriminating in channelopathies related to pain, although mutations in the genes encoding some
of the eight other NaV subtypes, identified so far, result in painful or painless diseases with strong
phenotypes [10–12]. Hence, numerous high-throughput screenings of venom banks from various
animals (spiders, scorpions, snakes, lizards, cone snails, etc.) have been performed on the NaV1.7
subtype, leading to the discovery of potential analgesic candidates mainly from spider venoms [13–15].
In fact, approximately 20 spider toxins, comprising between 26 and 35 amino acids and sharing the
same inhibitor cystine knot (ICK) architectural motif, are known to inhibit with high affinity the
NaV1.7 subtype (reviewed by [12,16]). However, the lack of target selectivity of most of these peptides
greatly impairs neuromuscular or cardiac safety issues, or both, and thus compromises their clinical
development as potential antinociceptive agents [17–21].
More than 10 years ago, and recently confirmed, a toxin identified as µ-theraphotoxin-Pspp1,
also named phlotoxin 1 (PhlTx1), was purified from the venom of a Phlogiellus genus spider endemic
to Papua New Guinea (uniprot.org/uniprot/P0DM14, [22–24]). PhlTx1 (4058.83 Da), characterized by
a 34-amino acid sequence with 3 disulfide bridges and structured around the ICK architectural motif,
was shown to belong to the NaV channel spider toxin (NaSpTx) family 1. This peptide was reported to
inhibit the NaV1.7 subtype expressed in Xenopus oocytes with high affinity and to produce, although
with lower efficiency than morphine, analgesic effects in a mouse model of inflammatory pain [22–24].
However, no or only little effect of PhlTx1 was detected on nociceptive heat stimulus responses in mice,
while the peptide co-administered with either the enkephalinase inhibitor thiorphan or the opioid
agonist buprenorphine, at concentrations that are ineffective alone, resulted in substantial analgesia
(Patent # WO 2015036734 A1, 2015, [25,26]). Moreover, application of the opioid antagonist naloxone
has been reported to potentiate noxious peripheral input into the spinal cord and to dramatically
reduce analgesia in NaV1.7-null mutant mice, as well as in a human NaV1.7-null mutant, suggesting
that NaV1.7 channel blockers alone may not replicate the analgesic phenotype of null mutant humans
and mice, but may be potentiated with exogenous opioids [27].
The aim of the present study was to consolidate the development of PhlTx1 as an antinociceptive
agent by studying the peptide interactions with a large panel of ion channels, to ensure its neuromuscular
and cardiac safety properties, and by evaluating the structure–activity relationships (SARs) of the
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molecule to improve its affinity and selectivity for the target of interest (i.e., the NaV1.7 subtype).
For this purpose, in vivo experiments were first carried out to evaluate the analgesic properties
of synthetic PhlTx1. Then, the effects of the peptide and alanine (Ala)-substituted variants were
investigated on cell lines stably overexpressing human (h) NaV subtypes, as well as two cardiac targets,
hCaV1.2 and the hKV11.1 subtype of voltage-gated potassium (KV) channels encoded by the human
ether-a-go-go-related gene (hERG), using automated whole-cell patch-clamp electrophysiology. Finally,
computational modelling was performed to propose a 3D-structure of PhlTx1 allowing the amino acids
involved in the efficiency of the molecule to be suggested.
2. Results
2.1. Chemical Synthesis and In Vitro Folding of PhlTx1
PhlTx1, a 34-amino acid toxin containing 6 cysteines (Figure 1A), was synthesized using the Fmoc
strategy (Figure 1Ba). It was recently reported (i) that the random disulfide oxidation of PhlTx1 is not
straightforward, (ii) that the directed disulfide bond formation strategy is five times more efficient
than the randomized one, and (iii) that both strategies drive toward the same rightly folded toxin [24].
The directed disulfide bond formation strategy is usually long and requires several chemistry and
purification steps. Therefore, we opted for the random disulfide oxidation strategy and tested different
folding protocols according to the nature and pH of the buffer and to the redox couple used which
are crucial parameters. The Tris-HCl buffer at pH 8.5 was associated with the reduced and oxidized
glutathione (GSH/GSSG, 1/1) while the HEPES buffer at pH 7.5 was associated with L-cysteine/L-cystine
(Cys/C–C, 1/0.1). Moreover, two chosen additives, 20% acetonitrile or glycerol, were used. The reaction
was left for 48 h at 4 ◦C to slow down the oxidation kinetics. The best folding condition was found to
be the Tris-HCl buffer and redox glutathione couple (Figure 1Bb).
Folding of the linear peptide generated a complicated profile with two main peaks, P1 and P2,
with P2 being surrounded by two side-peaks, P3 and P4. Mass analysis of these four peaks revealed a
similar mass corresponding to the full oxidation of the three disulfide bridges. The pharmacological
activity of 1 µM of these four peaks was tested on HEK-293 cell lines stably overexpressing the hNaV1.7
subtype. Only peak P1 was observed to strongly inhibit the hNaV1.7 current, with peak P2 and
peaks P3 and P4 showing moderate and no activity, respectively (data not shown). Therefore, peak
P1 was further analyzed in detail by analytical RP-HPLC chromatography. The results revealed the
existence of two peaks, P1’ and P1”, of similar areas and separated by retention times of more than
3 min (Figure 1Bc). Peaks P1’ and P1”, injected separately, generated again the two same peaks
(data not shown). This demonstrates that the synthetic product equilibrated between two structural
organizations, having different interaction properties with the column phase.
The influence of temperature (from 0 to 60 ◦C) was studied on the equilibrium between the two
forms, P1’ and P1”, of peak P1 (Figure 1Bd). Taking into account that the elution times of the different
forms of PhlTx1 were inversely proportional to the temperature, decreasing the temperature from 23
to 0 ◦C produced a decrease of the area of peak P1”, which finally disappeared at 0 ◦C, while that of
peak P1’ increased. Conversely, increasing the temperature from 23 to 60 ◦C was favorable to peak
P1”. In agreement, Nicolas et al. [24] have recently reported the presence of two peaks generated in
analytical RP-HPLC after the injection of a purified peak, unless the column was heated. The authors
proposed that at least one Pro residue involved in trans/cis isomerization would be responsible for the
existence of two PhlTx1 forms in equilibrium.
All of these characterizations demonstrate that the folding of PhlTx1 generates many forms visible
on analytical RP-HPLC analysis. The pharmacological activity of these forms clearly indicates that the
primary peak P1 was associated to the purest and the most active peptide, whatever the analytical
RP-HPLC conditions were.
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Figure 1. Primary structure, chemical synthesis, and in vitro folding of phlotoxin 1 (PhlTx1). (A) Primary
structure of PhlTx1, a 34-amino acid and amidated (*) peptide including 3 disulfide bridges, as defined
by homology with toxins from the NaV channel spider toxin (NaSpTx) family 1, i.e., occurring according
to the C1–C4, C2–C5, and C3–C6 pattern. (B) Chemical synthesis of PhlTx1. Analytical reversed
phase high performance liquid. chromatography (RP-HPLC) profiles, detected at 214 nm, of crude
peptide synthesis (a), crude peptide folding using the Tris-HCl buffer, the redox glutathione couple
and acetonitrile (b), and peak P1 (c) detected in (b). Note that the presence of two peaks in (c) limits
a non-well defined peak. (d) Effect of temperature on the equilibrium between the two peaks P1’ and
P1”, revealed by analytical RP-HPLC analysis of peak P1 at the indicated temperatures. The arrows
indicate the elution times of peaks P1’ and P1” at 23 ◦C.
2.2. Effects of PhlTx1 on a Mouse Model of NaV1.7-Mediated Pain
The in vivo analgesic effects of PhlTx1 were studied in a mouse model of NaV1.7-mediated pain,
based on intraplantar injection of toxin 1 from the Odonthobuthus doriae scorpion (OD1). When PBS
(+0.5% BSA) containing only OD1 (300 nM) was injected into the mice, the animal painful behavior,
quantified by the number of spontaneous licking, flinching, shaking, and biting of the paw, reached
a maximal value between 5 and 10 min following the injection, and then disappeared progressively
over 40 min. Under these conditions, the painful behavior occurring during the first 10 min following
co-injection of OD1 together with PBS was 117.5 ± 18.1 (n = 6 mice). This painful behavior was
markedly and significantly (P < 0.002) decreased by the co-injection of PBS, OD1, and 30, 300, or
1000 nM PhlTx1, i.e., 19.0 ± 11.6 (n = 6 mice), 7.5 ± 5.0 (n = 6 mice), and 6.2 ± 1.7 (n = 6 mice),
respectively (Figure 2), indicating that these peptide concentrations almost completely reversed the
OD1-induced pain.
Toxins 2019, 11, 484 5 of 18
Figure 2. Effects of PhlTx1 and D7A-PhlTx1 on OD1-induced painful behavior of mice. Painful
behavior was quantified by the number of spontaneous licking, flinching, shaking, and biting of the
paw occurring during the first 10 min following intraplantar injection of PBS + 0.5% BSA + 300 nM
OD1, added or not with 30, 300, or 1000 nM PhlTx1 and 300 or 1000 nM D7A-PhlTx1. Mean ± S.D. of
6 mice under each condition. (*): P < 0.002 when compared to OD1 (one-way ANOVA followed by
post-hoc pairwise t-tests with Bonferroni correction).
2.3. Effects of PhlTx1 on hNaV1.1-1.8, hCaV1.2, and KV11.1 Channel Subtypes
Whole-cell automated patch-clamp (QPatch HTX) experiments were performed on HEK-293
cells overexpressing hNaV1.1–1.8 channel subtypes, using the two electrophysiological protocols
detailed in the Materials and Methods section. During the classical “closed-open” protocol, all of
the hNaV subtypes were maintained in a resting state before the stimulation. Conversely, during the
“fully inactivated” protocol, most of the hNaV subtypes were maintained in an inactivated state before
the stimulation. These two different protocols allowed to test an eventual inactivated-state-dependent
effect of PhlTx1 on the hNaV subtypes. The results revealed, whatever the electrophysiological protocol
was, that 1 µM PhlTx1 was effective to inhibit hNaV1.1–1.7 currents, without any marked subtype
selectivity, while the hNaV1.8 current was unaffected (Figure 3A,B). Hence, the following increasing
order of IC50 values was obtained from the concentration–response curves of PhlTx1 effects on currents
flowing through the different channel subtypes: hNaV1.2 (73.7 ± 46.3 nM, n = 12 plates) ≈ hNaV1.3
(201.5± 109.8 nM, n = 6 plates)≈ hNaV1.7 (254.3 ± 147.6 nM, n = 5 plates)≈ hNaV1.1 (280.3 ± 117.7 nM,
n = 11 plates) < hNaV1.6 (491.2 ± 109.0 nM, n = 6 plates) << hNaV1.4 (> 2.1 ± 1.3 µM, n = 9 plates)
for tetrodotoxin-sensitive (TTX-S) channel subtypes, and hNaV1.5 (710.6 ± 32.7 nM, n = 10 plates) <
hNaV1.8 (> 10 µM, n = 4 plates) for tetrodotoxin-resistant (TTX-R) channel subtypes. Thus, all the
TTX-S hNaV channel subtypes studied, with the exception of hNaV1.4, were sensitive to PhlTx1,
as well as the TTX-R cardiac sodium channel subtype hNaV1.5 (although at hundred nanomolar
concentrations), while the TTX-R hNaV1.8 subtype was resistant to the peptide (at ten micromolar
concentrations). Additionally, PhlTx1 had a very low affinity for cardiac hCaV1.2 and hKV11.1 channel
subtypes overexpressed in CHO cells, since 10 µM of peptide had no effect on the hKV11.1 current
(n = 4 plates) and had only a low effect on the hCaV1.2 current (IC50 = 5.9 ± 2.1 µM, n = 6 plates;
Figure 3B).
Toxins 2019, 11, 484 6 of 18
Figure 3. Effects of PhlTx1 on HEK-293 cells overexpressing hNaV subtypes and on CHO
cells overexpressing hCaV1.2 and hKV11.1 subtypes, using whole-cell automated patch-clamp.
(A) Representative traces of sodium currents flowing through hNaV1.1–1.7 channel subtypes and
recorded during a “fully inactivated” (FI) protocol, before (in black) and after (in pink) exposure to
350 nM PhlTx1 (upper), and histogram of IC50 values (in nM) obtained from the concentration–response
curves of PhlTx1 effects on hNaV1.1–1.7 currents (lower). Each value represents the mean ± S.D. of data
obtained from n different plates (numbers in parentheses) realized in triplicate. Taking into account all
concentration–response curves, the mean value ± S.D. of nH was 1.15 ± 0.42. (B) Representative traces
of currents flowing through the indicated channel subtypes and recorded during a “closed-open” (CO)
protocol, before (in black) and after (in pink) exposure to 350 nM PhlTx1 (upper), and histogram of
IC50 values (in nM) obtained from the concentration–response curves of PhlTx1 effects on hNaV1.2,
1.5 and 1.7–1.8, hCaV1.2 and hKV11.1 currents (lower). Each value represents the mean ± S.D. of data
obtained from n different plates (numbers in parentheses) realized in triplicate. Taking into account all
concentration–response curves, the mean value ± S.D. of nH was 1.05 ± 0.15. The recording protocols
are detailed in the Materials and Methods section.
2.4. Structure–Activity Relationships of PhlTx1 Using an Alanine-Substituted Approach
The SAR study was carried out on PhlTx1 by replacing each amino acid of its sequence with
an Ala residue which possesses a non-bulky and chemically inert methyl group, with two exceptions:
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the first amino acid, which was a pyroglutamic acid-modified Ala, and the five C-terminal amino acids
that were removed. This Ala-substituted approach thus has the advantage to highlight the importance
of each amino acid in the peptide activity.
Linear forms of all peptide variants were synthesized and purified. The experimental conditions
of their folding were similar to those used to perform the folding of PhlTx1 (see Section 2.1). However,
only 8 of 21 variants were obtained with adequate biophysical characteristics (Table 1). These 8 variants
equilibrated between two forms, as observed for PhlTx1. The 13 other variants (L3A, Q5A, W6A, D10A,
P11A, S14A, P18A, N19A, Y20A, E23A, P27A, W28A, and Delta-C-ter, i.e., PhlTx1 without its five last
C-terminal residues) resulted in misfolded toxins, even after testing several different folding conditions.
Table 1. Production as well as biochemical and pharmacological characterizations of wild-type (WT)
PhlTx1 and its variants obtained by an alanine-substituted approach.
PhlTx1
Production BiochemicalCharacterization
Pharmacological
Characterization 1
Linear (mg) Oxidized(mg)
Folding
yield (%) Theo. Mass Exp. Mass
hNaV1.7
IC50 (nM)
WT 150 17.3 12 4055.72 4055.73 254.3 ± 147.6 (5)
A1Z * 9.8 1.1 11 4095.71 4095.71 171.5 ± 51.0 (5)
D7A 12.1 2.5 21 4011.73 4011.72 47.0 ± 40.9 (3)
S8A 9.9 0.55 6 4039.72 4039.70 179.5 ± 118.4 (4)
K12A 9.5 0.75 8 3998.66 3998.67 252.5 ± 13.6 (4)
K15A 8.6 1.1 13 3998.66 3998.66 706.4 ± 87.8 (5)
W24A 9.0 1.1 12 3940.68 3940.68 > 10000 (4)
K25A 9.2 2.0 22 3998.66 3998.67 > 10000 (3)
Y26A 11.1 2.5 23 3963.69 3963.68 > 10000 (6)
1 Mean ± S.D. of data obtained from n different plates (number in parentheses) realized in triplicate, obtained
by using the “fully inactivated” protocol; * Z: Pyroglutamic acid; Theo. Mass: theoretical mass; Exp. Mass:
experimental mass.
The presence of Ala-substituted amino acids close to the peptide C-terminus produced a loss
of variant affinity for the hNaV1.7 subtype, whereas little effect or even a gain of affinity of variants
was detected when the substituted amino acids were closer to the peptide N-terminus (Figure 4A
and Table 1). In particular, D7A-PhlTx1 had a 5.4-fold higher affinity for the hNaV1.7 subtype than
the wild-type peptide when using the “fully inactivated” protocol [i.e., 47.0 ± 40.9 nM (n = 3 plates)
and 254.3 ± 147.6 nM (n = 5 plates), respectively]. Indeed, when using the classical “closed-open”
protocol, this variant gained also in affinities for hNaV1.7 and hNaV1.5 subtypes [73.0 ± 23.7 nM vs.
308.9 ± 17.0 nM (n = 3 plates), and 93.3 ± 32.9 nM vs. 395.6 ± 121.6 nM (n = 3 plates), respectively], for
the hNaV1.2 subtype [47.3± 5.2 nM vs. 279.4± 6.1 (n = 3 plates)], and for hNaV1.8 and hCaV1.2 subtypes
[4.0 ± 0.5 µM vs. > 10 µM (n = 3–4 plates), and 799.6 ± 253.4 nM vs. 5.9 ± 2.2 µM (n = 3–6 plates),
respectively], while still remaining inactive on the KV11.1 subtype (Figures 3B and 4B).
The in vivo analgesic effects of D7A-PhlTx1 were also studied on the OD1-induced painful
behavior of mice. The mouse painful behavior occurring during the first 10 min was markedly and
significantly (P < 0.0003) decreased following the co-injection of PBS, OD1 (300 nM), and 300 or
1000 nM D7A-PhlTx1, i.e., 7.0 ± 3.1 (n = 6 mice) and 1.3 ± 0.5 (n = 6 mice), respectively, compared to
that following the injection of only PBS and OD1, i.e., 117.5 ± 18.1 (n = 6 mice) (Figure 2). As observed
with PhlTx1, these D7A-PhlTx1 concentrations almost completely reversed the OD1-induced pain.
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Figure 4. Structure–activity relationships of PhlTx1 using an alanine-substituted approach and
whole-cell automated patch-clamp. (A) Effects of PhlTx1 wild-type (WT) and variants on HEK-293 cells
overexpressing the hNaV1.7 subtype. Representative traces of the sodium current recorded during
a “fully inactivated” (FI) protocol, before (in black) and after (in color) exposure to 350 nM PhlTx1
wild-type and the indicated variants (upper), and histogram of IC50 values (in nM) obtained from the
concentration–response curves of peptide effects on the current (lower). Each value represents the
mean ± S.D. of data obtained from n different plates (numbers in parentheses) realized in triplicate.
Taking into account all concentration–response curves, the mean value ± S.D. of nH was 0.99 ± 0.42.
(B) Effects of D7A-PhlTx1 on HEK-293 cells overexpressing hNaV1.2, 1.5 and 1.7–1.8 subtypes and on
CHO cells overexpressing hCaV1.2 and hKV11.1 subtypes. Representative traces of currents flowing
through the indicated channel subtypes and recorded during a “closed-open” (CO) protocol, before (in
black) and after (in brown) exposure to 350 nM D7A-PhlTx1 (upper), and histogram of IC50 values (in
nM) obtained from the concentration–response curves of peptide effects on the currents (lower). Each
value represents the mean ± S.D. of data obtained from n different plates (numbers in parentheses)
realized in triplicate. Taking into account all concentration–response curves, the mean value ± S.D. of
nH was 1.06 ± 0.13.
2.5. Comparison of Amino Acid Sequences and 3D-Structures of PhlTx1 with Closely Related Toxins
The 3D-structure of PhlTx1, containing the ICK motif in its backbone conformation expected by
the amino acid sequence, was modelled by structural homology with the closest toxins from NCBI
basic local alignment search tool (BLAST) (Figure 5A and Table 2). As shown in Figure 5A, the
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Ala-substituted amino acids producing a complete loss of variant affinity for the hNaV1.7 subtype
are indicated in red (W24A, K25A and Y26A; IC50 > 10 µM, see Table 1); those resulting in a weak
(less than 3-fold) modification of variant affinity are indicated in orange (A1Z, S8A, K12A and K15A;
171 nM ≤ IC50 ≤ 706 nM, see Table 1); and the only one resulting in a more than 5-fold higher variant
affinity is indicated in green (D7A). Six of the 14 toxins extracted from NCBI BLAST had their
3D-structure defined by 2D-homonuclear 1H-NMR spectroscopy, which helped the computational
determination of PhlTx1 3D-structure. All the 3D-structures were similar except those of F8A-Pre1a
and Hs1a, which displayed the 3D-structure of peptide precursors with a long N-terminal, and those
of CcoTx2 and HwTx-I pointing out three β leaflets instead of two for the other peptides (Figure 5B).
Figure 5. 3D-Structure modelling of PhlTx1. (A) Ribbon representation indicating elements of secondary
structure. The structure topology is composed of a double stranded antiparallel β-sheet (arrows).
The three disulfide bonds are C2–C17, C9–C22, and C16–C29 (in yellow). The Ala-substituted amino
acids producing a complete loss of variant affinity for the hNaV1.7 subtype (IC50 > 10 µM) are colored
red (W24A, K25A and Y26A), those resulting in a less than 2.8-fold change variant affinity are colored
orange (A1Z, S8A, K12A and K15A), and the one (D7A) resulting in a gain of variant affinity (more
than 5-fold higher affinity) is colored green (see also Table 1). (B) Backbone peptide folding of PhlTx1
and toxins with PDB entries and showing the highest percentage of amino acid sequence identity with
PhlTx1 (PDB entries of CcoTx1: 6BRO, CcoTx2: 6BTV, F8A-Pre1a: 5I1X, Hs1a: 2MT7, HnTx-III: 2JTB,
and HwTx-I: 1QK6).
All of the toxins sharing between 45 and 76% of sequence identity with PhlTx1 were NaV, KV,
and CaV channel ligands (Table 2). All of them possess three strictly conserved amino acids (G4, P11,
and W28). Some of these toxins, such as Cd1a, CcoTx1, and HnTx-III, were described to target the
NaV1.7 subtype with nanomolar affinities (IC50 between 2 and 232 nM, Table 2) and, thus, to have
potential implications in the pain therapy field [28–30].
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Table 2. Comparison of amino acid sequences between PhlTx1 and the 14 most similar or well-documented toxins described in the literature. The sequence alignment
was performed with ClustalIW (version 12.1 from Emboss programs, EBlosum62 matrix for two pair alignment). The cysteine scaffold and conserved residues are
indicated in blue and red, respectively. The Ala-substituted amino acids producing a complete loss of variant affinity for the hNaV1.7 subtype are colored red (W24A,
K25A, and Y26A), those resulting in a less than 2.8-fold change variant affinity are colored orange (A1Z, S8A, K12A, and K15A), and the one (D7A) resulting in a gain
of variant affinity is colored green (see also Table 1). The percentage of sequence identity with PhlTx1, the known targets, and the mean IC50 value (in nM) reported for
the hNaV1.7 subtype are described in the right-hand columns, according to data sourced from Pubmed and ArachnoServer [31].
Name * Amino Acid Sequence Identity Target IC50/hNaV1.7 (nM)
PhlTx1 (µ-TRTX-Pspp-1) – A –CLGQW D S CDP K AS K CCPNYACE WKY PWCRYKLF- 100% NaV 254
OAIP2 –D–CLGQWASCEPKNSKCCPNYACTWKYPWCRYRAGK 76% ? -
TlTx1 (κ-TRTX-Tb1a) -AA–CLGMFESCDPNNDKCCPNRECNRKHKWCKYKLW- 59% KV -
Osp1b (µ-TRTX-Osp1b) –E–CLGWMKGCEPKNNKCCSSYVCTYKYPWCRYDL– 58% NaV -1
TlTx2 (κ-TRTX-Tb1b) -DD–CLGMFSSCDPKNDKCCPNRVCRSRDQWCKYKLW- 56% KV -
Cd1a (β-TRTX-Cd1a) –D–CLGWFKSCDPKNDKCCKNYSCSRRDRWCKYDL– 55% NaV 16 [30]
CcoTx1 (β-TRTX-Cm1a) –D–CLGWFKSCDPKNDKCCKNYTCSRRDRWCKYDL– 55% NaV 2-130 [29,32]
CcoTx2 (β-TRTX-Cm1b) –D–CLGWFKSCDPKNDKCCKNYTCSRRDRWCKYYL– 55% NaV 95 [32]
TlTx3 (κ-TRTX-Tb1c) -DD–CLGMFSSCDPNNDKCCPNRVCRVRDQWCKYKLW- 53% KV -
Pre1a (β/δ-TRTX-Pre1a) -ED–CLGWFSRCSPKNDKCCPNYKCSSKDLWCKYKIW- 53% NaV 114 [33]
Hs1a GND–CLGFWSACNPKNDKCCANLVCSSKHKWCKGKL- 52% NaV - [34]
HnTx-III (µ-TRTX-Hhn2a) —-GCKGFGDSCTPGKNECCPNYACSSKHKWCKVYLGK 50% NaV 232 [28]
Ccy1b (µ-TRTX-Ccy1b) -DD–CLGFFKSCNPDNDKCCENYKCNRRDKWCKYVL– 48% NaV - [13]
Pmr1a (µ-TRTX-Pmr1a) -DD–CLGMFSSCDPDNDKCCEGRKCNRKDKWCKYVL– 48% NaV - [35]
HwTx-I (µ/ω-TRTX-Hs1a) —-ACKGVFDACTPGKNECCPNRVCSDKHKWCKWKL– 45% NaV/CaV <200 [36]
* The Greek letter(s) before the toxin name is associated to its type of action: µ for NaV channel inhibition, β for shift in the voltage-dependence of NaV channel activation, δ for delay
inactivation of NaV channels,ω for CaV channel inhibition, and κ for KV channel inhibition. TRTX, theraphotoxin.
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3. Discussion
The present study was undertaken to better characterize PhlTx1, previously described as a potential
antinociceptive agent, in order to consolidate the clinical development of this peptide. The research
strategy consisted of (1) the in-house chemical synthesis of PhlTx1, (2) a deep pharmacological
evaluation (from in vivo to individual cells) of the synthetic peptide, (3) a SAR study carried out on
PhlTx1, using an Ala-substituted approach, to improve the peptide affinity and selectivity, and (4)
a computational modelling of 3D-structure to better understand the peptide effects already studied for
closely related toxins.
The effects of synthetic PhlTx1 were studied on HEK-293 cells overexpressing hNaV1.1–1.8
subtypes and on CHO cells overexpressing hCaV1.2 and hKV11.1 subtypes, using a whole-cell
automated patch-clamp technique. This study was performed (i) to reinforce, on human NaV subtypes,
the previous evaluation of the peptide selectivity profile performed on undetailed species of NaV
subtypes, and (ii) to ensure its cardiac safety properties. More than ten years ago, the effects of PhlTx1
were studied on different NaV subtypes expressed with the β1 subunit in Xenopus oocytes [22,23].
At a concentration of 1 µM, the peptide produced greater than 90% inhibition of NaV1.7 current,
a 35–39% inhibition of NaV1.4 and 1.6 currents, and less than 10% inhibition of NaV1.1–1.3, 1.5 and
1.8 currents, as well as of Drosophila Para/TipE current. The comparison of these results obtained from
undetailed or Drosophila species of NaV subtypes expressed in Xenopus oocytes with those we obtained
from human NaV subtypes stably overexpressed in mammalian cell lines is not accurate, although
similar mean IC50 values were determined for PhlTx1 interaction with the NaV1.7 subtype (i.e., 260 and
254–309 nM, respectively). Therefore, this study allows the confirmation of both the peptide efficacy on
the human NaV1.7 subtype and some of its cardiac safety properties since, in particular, the two cardiac
hCaV1.2 and hKV11.1 targets were relatively saved (i.e., IC50 ≥ 5.9 µM) compared to the hNaV1.5
subtype (i.e., IC50 = 710.6 nM).
Compared to toxins belonging to the NaSpTx family 1, such as HnTx-I, HnTx-III, Hd1a, HnTx-IV,
ProTx-III, Cm1a, GpTx-1, and HwTx-IV, previously reported in the literature to interact with the
hNaV1.7 subtype, PhlTx1 is among the lowest potent peptides [13,14,28,29,34,37–40] (but see [21]).
In addition, the peptide displayed a less than 10-fold selectivity towards the TTX-R (with the exception
of hNaV1.8) and other TTX-S (with the exception of hNaV1.4) hNaV subtypes (mean IC50 values between
74 and 711 nM). It is worth noting that relatively similar IC50 values were obtained from the “fully
inactivated” and classical “closed-open” protocols, suggesting that no inactivated-state-dependent
effect of PhlTx1 occurred on the studied hNaV subtypes (see also [24]). The poor peptide selectivity
towards the hNaV1.1 and 1.3 subtypes may be an advantage since these two subtypes have been
reported to also be involved in pain pathways (see for review [12]). That towards the hNaV1.2 subtype,
located at the level of the central nervous system, will have no important consequence taking into
account the peripheral administration of PhlTx1. Therefore, the only problem of the peptide is its poor
selectivity towards the hNaV1.5 and 1.6 subtypes since its potential use as an analgesic molecule may
be associated with in vivo cardiac and neuromuscular side-effects, respectively.
The antinociceptive properties as well as the cardiac and neuromuscular side-effects of PhlTx1
were evaluated in vivo on OD1-induced painful behavior of mice. The results revealed that the peptide
exhibited antinociceptive properties since intraplantar co-injection of OD1 (300 nM) and PhlTx1 (from
30 to 1000 nM) was efficient to almost completely eliminate the animal painful behavior induced by
the injection of only OD1. Interestingly, no sign of cardiac or neuromuscular side-effects were detected
during these experiments. This strongly suggests that, under our experimental conditions, the poor
peptide selectivity towards the hNaV1.5 and 1.6 subtypes has no consequence in vivo. Anti-allodynic
and analgesic effects of intrathecal injection of PhlTx1, without signs of neurotoxicity, were previously
reported in a mouse model of acute and inflammatory neuropathic (paw formalin injection) pain [23,24].
However, intraplantar and intraperitoneal injections of the peptide were shown to be ineffective to
produce analgesia in a Complete Freund’s Adjuvant (CFA)-induced heat hyperalgesia mouse model [25]
and to affect mouse acute heat responses [26], respectively. It is likely that the discrepancy between
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these results is due to the route of PhlTx1 administration or the mouse model used, or both, rather than
the dose of injected peptide. Further experiments are however needed to draw a definitive conclusion.
The effects of 9 toxins, showing a higher affinity than PhlTx1 for the hNaV1.7 subtype (with
the following increasing order for mean IC50 values (between 0.9 and 130 nM): Pn3a, Df1a-NH2,
m3-HwTx-IV, GpTx-1, ProTx-III, Cd1a, Df1a-OH, CcoTx2, and CcoTx1), were also tested in vivo on
OD1-induced painful behavior of mice [14,18,20,26,29,30,32,39,41]. Although Pn3a has the highest
affinity for the hNaV1.7 subtype (but see [24]), close doses of intraperitoneal injection of this toxin
and intraplantar injection of PhlTx1 have similar effects on OD1-induced painful behavior of mice.
In addition, a synergistic action between PhlTx1 or Pn3a and low, non-therapeutic doses of opioids
(such as oxycodone or buprenorphine) or enkephalinase inhibitors (such as thiorphan) were recently
shown to induce analgesia during the phase II of inflammatory pain in mice. From this point of
view, PhlTx1 was reported to be more efficient than Pn3a (Patent # WO 2015036734 A1, 2015; [25,26]).
This questions the existence of a correlation between a peptide hNaV1.7 affinity and its in vivo effects on
rodent pain models. The evaluation of m3-HwTx-IV, GpTx-1, and ProTx-III, performed under similar
experimental conditions as that of PhlTx1, revealed that these toxins produced a 10-, 5-, and 2-fold
decrease of animal painful behavior induced by OD1, respectively. However, marked neuromuscular
side-effects were reported for m3-HwTx-IV and GpTx-1. The other five toxins were also efficient
to diminish or completely reverse the OD1-induced manifestations of pain but at relatively high
concentrations (1 µM for Cd1a, CcoTx1, and CcoTx2, and 10 µM for Df1a-NH2 and Df1a-OH).
The relatively low affinity of PhlTx1 for the hNaV1.7 subtype motivated a SAR study. Our folding
strategy provided reasonable yield of production. Its limitation appeared for some variants for which
we were unable to obtain the desired peptide. In these cases, the directed folding strategy could
be useful [24]. Among the eight peptide variant forms tested on HEK-293 cells overexpressing the
hNaV1.7 subtype, W24A-, K25A-, and Y26A-PhlTx1 were shown to completely lose affinity for this
type of channel subtype, indicating that the C-terminal residues Trp24, Lys25, and Tyr26 are essential
for hNaV1.7 inhibition. It has already been mentioned in the literature that toxins belonging to the
NaSpTx family 1 display positively charged amino acids Lys25, His26, Lys27, Lys30, surrounded by
hydrophobic Phe5 and Trp28 clustered on one molecule face, which may be involved in the peptide
interactions with TTX-sensitive NaV channels [13,15,37,38]. However, PhlTx1 possesses only two
of the four positively charged amino acids (K25 and R30 instead of K30), while the hydrophobic
amino acids are almost preserved (Q5, instead of F5, and W28). This may explain the relatively
low affinity of the peptide for the hNaV1.7 subtype, compared to the most potent toxins belonging
to the NaSpTx family 1 which possess well-preserved H26 and K30, such as HnTx-III and HwTx-1
(IC50 < 200 nM and IC50 = 232 nM, respectively; see Table 2), as well as the well-known previously
described antinociceptive toxins ProTx-III and GpTx-1 (IC50 = 2 nM for both, [14,40]). In addition,
comparison of amino acid sequences between PhlTx1 and the 14 most similar or well-documented
toxins described in the literature reveals that the three highly conserved residues Gly4, Pro11, and
Trp28 are also crucial to govern hNaV activity or to reinforce the hNaV1.7 inhibitory potency of ICK
toxins [24,29,42,43]. This would have been further confirmed if correctly folded G4A-, P11A-, and
W28A-PhlTx1 could have been obtained. On the other hand, the affinity of A1Z-, S8A-, K12A-, and
K15A-PhlTx1 for hNaV1.7 was only weakly modified, which strongly suggests that the N-terminal
group and the residues Ser8, Lys12, and Lys15 are not particularly important for the peptide hNaV1.7
activity. Finally, D7A-PhlTx1 was the only variant showing an improved affinity for hNaV1.7 (mean
IC50 values of 47–73 nM for D7A-PhlTx1 vs. 254–309 nM for PhlTx1). However, a gain of affinity
(between 2.5- and 7.4-fold) was also observed not only for the hNaV1.2 and 1.8 subtypes, but also for
the hNaV1.5 and hCaV1.2 subtypes.
4. Conclusions
The results obtained from the characterization of physicochemical and functional properties of
PhlTx1 and some of its variants, on a wide range of ion channel subtypes, highlight the identification
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of a relatively interesting variant, D7A-PhlTx1, with potent analgesic effects in a mouse model of
NaV1.7-mediated pain induced by OD1 but with a low improved affinity for the hNaV1.7 subtype and
a modest degree of selectivity towards the other hNaV subtypes.
5. Materials and Methods
5.1. Chemical Synthesis and In Vitro Folding of PhlTx1 and Its Variants
The assembly of different peptides was carried out using the stepwise solid-phase method
with dicyclohexylcarbodiimide/1-hydroxy-7-azabenzotriazole (HOAT) as coupling reagents and
N-methylpyrrolidone as solvent. Fmoc-protected amino acids were used with the following side chain
protections: tert-butyl ester (Glu, Asp), tert-butyl ether (Ser, Thr, Tyr), trityl group (Cys, His, Asn, Gln),
2,2,5,7,8-pentamethyl-chromane-6-sulfonyl group (Arg), and tert-butyloxycarbonyl group (Trp). The
peptides were assembled on a Fmoc-Phe(OtBu)-Wang resin (0.5 mmol/g loading), with the exception
of the C-terminal-deleted (Delta-C-ter) variant which was assembled on a Fmoc-Cys(Boc)-Wang resin
(0.55 mmol/g loading). Automated chain assembly was performed on a standard Applied Biosystems
433 peptide synthesizer (Applied Biosystems, Foster City, CA, USA). The different syntheses were
run on a modified version of the Applied Biosystems standard 0.1-mmol small-scale program using
0.05 mmol of each resin. The linear peptide forms were purified from the crude synthetic products
by analytical reversed-phase high pressure liquid chromatography (RP-HPLC). The maturation of
peptides was performed in 100 mM tris-HCl buffer (pH 8) supplemented with 2 mM of reduced (GSH)
and oxidized glutathione (GSSG), during 48 h at 4 ◦C. Mass spectrometry (MS) analysis was performed
on a 4800 MALDI TOF/TOF™ Analyzer (Applied Biosystems).
Protected amino acid derivatives, resins, and dicyclohexylcarbodiimide were from Novabiochem
(Meudon, France), HOAT from Applied Biosystems (Courtaboeuf, France), N-methylpyrrolidone
from Carlo Erba Reactifs - Sds (Peypin, France), and GSH, GSSG, and L-cysteine from Sigma-Aldrich
(Saint-Quentin-Fallavier, France).
5.2. Predicted 3D-Structure of PhlTx1
Computational modelling was performed, using the PyMOL software, to deduce the 3D-structure
of PhlTx1 from those of closely related toxins archived in the protein data bank (PDB): ceratotoxin-1
(Cm1a, PDB: 6BRO), ceratotoxin-2 (Cm1b, PDB: 6BTV), F8A variant of Pre-1a (PDB: 5I1X), peptide
Hs1a (PDB: 2MT7), hainantoxin-III (HnTx-III, PDB: 2JTB) and huwentoxin-I (HwTx-I, PDB: 1QK6).
5.3. Toxins and Chemicals
Lyophilized synthetic PhlTx1 wild-type and variant forms (purity rate > 97%) were dissolved in
appropriate solutions to give adequate stock solutions. All compounds used as reference molecules to
pharmacologically validate the current flowing through each channel subtype, as indicated in Table 3,
were purchased from Sigma-Aldrich and Smartox Biotechnology (Saint-Egrève, France).
Table 3. Compounds used as reference molecules to pharmacologically validate the current flowing
through each hNaV, hCaV, and hKV channel subtype.
Channel Subtype
Drug Reference
Name Molecular Mass Purity Rate Provider IC90–95 1 (µM)
hNaV1.1–1.8 Tetrodotoxin (citrate) 319.27 > 98% Sigma-Aldrich 1
hCaV1.2
Nifedipine 346.33 > 98% Sigma-Aldrich 10
Cadmium (chloride) 1 183.32 > 99% Sigma-Aldrich 200
hKV11.1 BeKm-1 4091.70 > 97% Smartox Biotechnology 1
1 Compound concentration necessary to inhibit 90–95% of current.
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The toxins were dissolved in distilled water to give a 100 µM stock solution, and the chemicals were
dissolved in 100% dimethylsulfoxyde (DMSO, Sigma-Aldrich) to give a 10 mM stock solution. Just prior
to experiments, successive dilutions were performed in the appropriate standard physiological medium
(supplemented with 0.1% bovine serum albumin (BSA, Sigma-Aldrich) for toxins to avoid plastic
adherence, and with 0.3% DMSO for chemicals to maintain solubility), to give the compound final
concentrations indicated in the text.
5.4. Cell Lines Used for Functional Assays
Generation of inducible cell lines was achieved by cloning cDNAs encoding for hNaV1.2
(NM_021007.2) and hNaV1.5 (NM_000335) subtypes into the Flp-In®T-Rex®expression vector
(Invitrogen, USA) and subsequently transfecting them into human embryonic kidney (HEK)-293
cell line, using the FuGENE®transfection reagent (Promega, France). The cell lines were cultured
under standard conditions (37 ◦C, 5% CO2) in Dulbecco’s modified Eagle’s medium (DMEM) with
GlutaMAXTM supplement (Gibco, Thermo Fisher Scientific, Villebon-sur-Yvette, France), supplemented
with 10% fetal calf serum (Invitrogen), 50 µg/mL hygromycin (Invitrogen), and 15 µg/mL blasticidin
(Invivogen). They were sub-cultured every 3–4 days using accutase®(Sigma-Aldrich) or TrypLE Select
(Gibco) enzyme. The cell line passage number was less than 15 on the day of experiments. Doxycycline
(BD Biosciences, France) was added to induce target expression, at least between 12 and 24 h prior
to experiments.
Recombinant HEK-293 cell lines, stably overexpressing the other hNaV subtypes, were purchased
from SB Drug Discovery (UK; hNaV1.3 and 1.4), ChanTest (Cleveland, OH, USA; hNaV1.6) and
Eurofins (St Charles, MO, USA; hNaV1.1, 1.7 and 1.8/β1). These cell lines were cultured in
Eagle’s minimum essential medium (MEM, Sigma-Aldrich; hNaV1.3 and 1.4), in DMEM/F-12 with
GlutaMAXTM supplement (Gibco; hNaV1.1, 1.6 and 1.8/β1) or in suspension in a FreeStyleTM 293
expression medium (Gibco, hNaV1.7). The Chinese hamster ovary (CHO) cells heterologously
overexpressing hCaV1.2/β2/α2δ1 (purchased from ChanTest) were cultured in Ham’s F12 nutrient mix
with GlutaMAXTM medium (Gibco), and those overexpressing hKV11.1 (purchased from B’SYS GmbH,
Switzerland) in DMEM/F-12 nutrient mixture Ham’s medium (Sigma-Aldrich). All culture media
contained 10% fetal bovine serum (Gibco) and selected antibiotics and additives, as recommended by
the manufacturers. The cells were grown in flasks (37 ◦C, 5% CO2), and sub-cultured every 3–4 days
using TrypLE Select enzyme. The cell line passage number was less than 20 on the day of experiments.
5.5. Automated Whole-Cell Patch-Clamp Electrophysiology
The effects of synthetic PhlTx1 and some of its variants were investigated on the cell lines
overexpressing hNaV1.1–1.8, hCaV1.2, and hKV11.1 subtypes, using the automated QPatch HTX
patch-clamp system (Sophion Bioscience, Denmark), allowing current recordings in whole-cell
configuration and both signal acquisition and data analyses, as previously reported [15]. On the day of
their use, HEK-293 and CHO cells were transferred into Eppendorf tubes containing a FreeStyleTM
293 expression medium (Gibco) which were then placed in the automated electrophysiology platform.
The extracellular medium composition for hNaV-overexpressing HEK-293 cells was (in mM): NaCl
154, KCl 4, CaCl2 2, MgCl2 1, and HEPES 10 (pH 7.4 adjusted with NaOH), and that of intracellular
(i.e., path-clamp pipette) medium: CsF 150, EGTA/CsOH 1/50, HEPES 10, NaCl 10, MgCl2 1, and CaCl2
1 (pH 7.4 adjusted with CsOH). The extracellular medium composition for hCaV1.2-overexpressing
CHO cells was (in mM): NaCl 145, KCl 4, CaCl2 10, and HEPES 10 (pH 7.4 adjusted with NaOH), and
that of intracellular medium: CsF 27, CsCl 112, EGTA 8.2, HEPES 10, NaCl 2, and Mg-ATP 4 (pH 7.4
adjusted with CsOH). The extracellular medium composition for hKV11.1-overexpressing CHO cells
was (in mM): NaCl 145, KCl 4, CaCl2 2, MgCl2 1, HEPES 10, and D-glucose 10 (pH 7.4 adjusted with
NaOH), and that of intracellular medium: KCl 120, CaCl2 5.4, EGTA 10, HEPES 10, Mg-ATP 4, and
MgCl2 1.75 (pH 7.4 adjusted with KOH). Synthetic PhlTx1 and variants were diluted in the extracellular
medium supplemented with bovine serum albumin (0.1%), to give the final concentrations indicated
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in the text. The time of cell incubation with peptides and reference molecules was adjusted to achieve
steady-state effects, i.e., between approximately 2 and 7 min. The experiments were carried out at
room temperature (20-22 ◦C).
In addition to the classical “closed-open” protocol, a “fully inactivated” protocol was also used
to test an eventual inactivated-state-dependent effect of peptides on hNaV subtypes. During the
“closed-open” protocol, the hNaV-overexpressing HEK-293 cells were maintained at a holding potential
of either−90 mV (hNaV1.5) or−100 mV (other hNaV subtypes), and currents were elicited at a frequency
of 0.2 Hz by 20 ms test-pulses to −20 mV (hNaV1.2 and 1.7), −40 mV (hNaV1.5) or 10 mV (hNaV1.8),
preceded by 40 ms (hNaV1.7) or 200 ms (hNaV1.5) pulses to −120 mV, or not (hNaV1.2 and 1.8).
The hCaV1.2-overexpressing CHO cells were maintained at a holding potential of −50 mV, and currents
were elicited at a frequency of 0.05 Hz by 200 ms test-pulses to 0 mV. The hKV11.1-overexpressing CHO
cells were maintained at a holding potential of −80 mV, and tail currents were elicited at a frequency
of 0.07 Hz by 5 s test-pulses to −50 mV, preceded by 4.8 s pulses to 20 mV following 20 ms pulses
to −50 mV. During the “fully inactivated” protocol, the hNaV-overexpressing HEK-293 cells were
maintained at a holding potential of either −40 mV (hNaV1.1, 1.2 and 1.6) or −50 mV (other hNaV
subtypes), and currents were elicited at a frequency of 0.2 Hz by 20 ms test-pulses to −40 mV (hNaV1.5)
or −20 mV (other hNaV subtypes), preceded by 40 ms (hNaV1.3 and 1.4) or 20 ms (other hNaV subtypes)
pulses to −120 mV. The leakage current was not compensated for.
The concentration–response relationships were established by plotting the peak amplitude of
the sum of ten cell currents recorded in the presence of a given molecule (Pm), expressed relative
to that of the sum of these currents recorded before molecule application (Pc), against the molecule
concentration ([m]). The theoretical concentration-response curves were calculated from typical
sigmoid nonlinear regressions through data points according to the Hill equation (QPatch assay
software): Pm/Pc = 1/[1 + ([m]/IC50) nH], where IC50 is the molecule concentration necessary to inhibit
50% of the response, and nH is the Hill number.
5.6. Mouse Model of NaV1.7-Mediated Pain
The peptide analgesic effects were studied at room temperature in a mouse model of
NaV1.7-mediated pain, based on intraplantar injection of toxin 1 from the Odonthobuthus doriae
scorpion (OD1, Smartox Biotechnology) that potently enhances the activity of the NaV1.7 subtype
by inhibiting channel fast inactivation and increasing peak current, as previously described [18].
The experiments were performed on 36 adult male C57BL/6 mice (Mus musculus, 8 weeks of age and
20–25 g of body weight), purchased from Charles River Laboratories (St Germain Nuelles, France).
The animals were acclimatized for at least 48 h before experiments at the IGF animal facility where
they were housed in a 12 h light/dark cycle and controlled temperature room, 3–4 per cage containing
standard rodent chow and with ad libitum access to food and water. The experiments were conducted
in compliance with the guidelines established by the French Council for animal care “Guide for the Care
and Use of Laboratory Animals” (EEC86/609 Council Directive–Decree 2001-131), and the experimental
protocols were approved by the French General Directorate for Research and Innovation (project
APAFIS#747-2016012216345875v4 authorized to E. Bourinet) on 3 February 2019.
The painful behavior of mice was quantified by the number of spontaneous licking, flinching,
shaking, and biting of the paw, for 10 min after intraplantar injection with 40 µL volume under light
isoflurane anesthesia (AErrane®, Baxter S.A., Lessines, Belgique; 2% for 0.5–1 min), using a 50 µL
micro-syringe. The injected solution comprised phosphate buffered saline (PBS) supplemented with
0.5% BSA and containing either 300 nM OD1 alone or OD1 and 30, 300 or 1000 nM of a given synthetic
peptide. The study was experimentally designed, on the basis of previous experiments, to have six
animals per group. The experiments were video recorded and blind analysis of mouse painful behavior
was performed, off-line, by an observer unaware of which treatment each animal had received.
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5.7. Statistical Analyses
Data are expressed as means ± standard deviations (S.D.) of either n independent experimental
plates realized in triplicate or n mice. The statistical comparison of values was carried out using (i) the
parametric two-tailed Student’s t-test (either paired samples for comparison within a single population
or unpaired samples for comparison between two independent populations), or (ii) the one-way analysis
of variance (ANOVA for comparison between the means of three or more independent populations)
followed, if F was significant and if no variance inhomogeneity occurred, by post-hoc pairwise t-tests
with Bonferroni correction. Differences between values were considered to be statistically significant at
P ≤ 0.05.
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